We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Alvontech | NASDAQ:ALVO | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.35 | -2.53% | 13.51 | 13.49 | 13.53 | 13.60 | 13.45 | 13.60 | 34,474 | 20:43:18 |
By Chris Wack
Shares of Alvotech and Teva Pharmaceutical Industries Ltd. were both up after the U.S. Food and Drug Administration has accepted for review a Biologics License Application for AVT04, Alvotech's proposed biosimilar to Stelara ustekinumab.
Stelara, developed by Johnson & Johnson's Janssen Pharmaceuticals, is prescribed to treat a variety of inflammatory conditions, such as Crohn's disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis.
Alvotech shares were up 6% to $10.68, and Teva Pharma shares were up 6% to $10.55. The companies anticipate that the FDA's review will be completed in second half of 2023.
In August 2020, Alvotech and Teva entered into a strategic partnership for the exclusive commercialization in the U.S. of five of Alvotech's biosimilar product candidates. In May 2022, Alvotech said that a confirmatory clinical, safety and efficacy study for AVT04 had met its primary endpoint, demonstrating therapeutic equivalence between Alvotech's biosimilar candidate and the reference product in patients with moderate to severe chronic plaque-type psoriasis.
Also in May 2022, Alvotech reported positive top-line results from a pharmacokinetic similarity study for AVT04.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
January 06, 2023 14:06 ET (19:06 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Alvontech Chart |
1 Month Alvontech Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions